Search results
Results from the WOW.Com Content Network
Weight gain is an increase in body weight. This can involve an increase in muscle mass , fat deposits , excess fluids such as water or other factors. Weight gain can be a symptom of a serious medical condition.
Hyperglycemia may be caused by: diabetes, various (non-diabetic) endocrine disorders (insulin resistance and thyroid, adrenal, pancreatic, and pituitary disorders), sepsis and certain infections, intracranial diseases (e.g. encephalitis, brain tumors (especially if near the pituitary gland), brain haemorrhages, and meningitis) (frequently ...
Type 1 diabetes risk is slightly higher for children whose mothers are obese or older than 35, or for children born by caesarean section. [34] Similarly, a child's weight gain in the first year of life, total weight, and BMI are associated with slightly increased type 1 diabetes risk. [34]
Apples. The original source of sweetness for many of the early settlers in the United States, the sugar from an apple comes with a healthy dose of fiber.
When diabetes is the cause, physicians typically recommend an anti-diabetic medication as treatment. From the perspective of the majority of patients, treatment with an old, well-understood diabetes drug such as metformin will be the safest, most effective, least expensive, and most comfortable route to managing the condition.
In populations with a low risk for type 2 diabetes, in lean subjects and in women with auto-antibodies, there is a higher rate of women developing type 1 diabetes. [ 98 ] Children of women with GDM have an increased risk for childhood and adult obesity and an increased risk of glucose intolerance and type 2 diabetes later in life. [ 103 ]
(Reuters) -Eli Lilly's weight-loss drug, Zepbound, drastically cut the risk of developing type 2 diabetes in overweight or obese pre-diabetic adults after three years of weekly injections, the ...
Thiazolidinediones may cause slight weight gain but decrease "pathologic" abdominal fat (visceral fat), and therefore may be prescribed for diabetics with central obesity. [115] Thiazolidinedione has been associated with heart failure and increased cardiovascular risk; so it has been withdrawn from the market in Europe by EMA in 2010.